Compare DexCom, Inc. (DXCM) vs Victoria's Secret & Co (VSXY) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

Victoria's Secret (VSXY) trades at $83.30, up 1.68% today, with a bullish technical outlook and strong analyst support. Recent earnings beats in Q3 2025 through Q1 2026 and a 44.9% international sales surge in Q1 2026 highlight operational momentum. The stock shows improving fundamentals with net income rising to $165 million in 2025 and a consensus price target of $88.56, suggesting 6% upside from current levels.

The outlook remains positive driven by international expansion and margin recovery, but risks include competitive pressures and reliance on consumer spending. With no sell ratings from analysts and institutional backing for the board, VSXY presents a growth opportunity with manageable risks for investors seeking apparel retail exposure.